Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

20183,943 citationsJournal Articlebronze Open Access

Authors

Stephen J. Schuster · University of Pennsylvania

Michael Bishop · University of Chicago

Constantine S. Tam · University of Melbourne

Edmund K. Waller · Emory University

Peter Borchmann · University Hospital Cologne

Joseph P. McGuirk · The University of Kansas Cancer Center

Ulrich Jäger

Abstract

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).

Topics & Keywords

CAR-T cell therapy research Integrated Circuits and Semiconductor Failure Analysis Virus-based gene therapy research

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 1, pp. 45-56

DOI: 10.1056/nejmoa1804980

Field-Weighted Citation Impact: 131.03